International Stem Cell Corp. (ISCO) Gearing Up for Transformational 2014
International Stem Cell Corp. is a publicly traded biotechnology company concentrating on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. The company’s core technological platform, parthenogenesis, creates pluripotent human stem cells from unfertilized eggs. With treatment possibilities for patients with diseases of the eye, the nervous system, and the liver, parthenogenesis can take the field of regenerative medicine in a whole new direction. The technology has strong therapeutic potential for treating hundreds of millions of individuals whose treatability has been limited by a lack of available, safe immune-matched human…